Skip to main content
Top
Published in: Virology Journal 1/2005

Open Access 01-12-2005 | Research

EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas

Authors: Abdelmajid Khabir, Hela Karray, Sandrine Rodriguez, Mathieu Rosé, Jamel Daoud, Mounir Frikha, Tahia Boudawara, Jaap Middeldorp, Rachid Jlidi, Pierre Busson

Published in: Virology Journal | Issue 1/2005

Login to get access

Abstract

Background

Undifferentiated nasopharyngeal carcinomas are rare in a majority of countries but they occur at a high incidence in South China and to a lesser extent in North Africa. They are constantly associated with the Epstein-Barr virus (EBV) regardless of patient geographic origin. In North Africa, the distribution of NPC cases according to patient age is bi-modal with a large group of patients being around 50 years old (80%) and a smaller group below 25 years old. We and others have previously shown that the juvenile form of NPC has distinct biological characteristics including a low amount of p53 and Bcl2 in the tumor tissue and a low level of anti-EBV IgG and IgA in the peripheral blood.

Results

To get more insight on potential oncogenic mechanisms specific of these two forms, LMP1 abundance was assessed in 82 NPC patients of both groups, using immuno-histochemistry and semi-quantitative evaluation of tissue staining. Serum levels of anti-EBV antibodies were simultaneously assessed. For LMP1 staining, we used the S12 antibody which has proven to be more sensitive than the common anti-LMP1 CS1-4 for analysis of tissue sections. In all NPC biopsies, at least a small fraction of cells was positively stained by S12. LMP1 abundance was strongly correlated to patient age, with higher amounts of the viral protein detected in specimens of the juvenile form. In contrast, LMP1 abundance was not correlated to the presence of lymph node or visceral metastases, nor to the risk of metastatic recurrence. It was also independent of the level of circulating anti-EBV antibodies.

Conclusion

The high amount of LMP1 recorded in tumors from young patients confirms that the juvenile form of NPC has specific features regarding not only cellular but also viral gene expression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Busson P, Keryer C, Ooka T, Corbex M: EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 2004, 12: 356-360. 10.1016/j.tim.2004.06.005CrossRefPubMed Busson P, Keryer C, Ooka T, Corbex M: EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 2004, 12: 356-360. 10.1016/j.tim.2004.06.005CrossRefPubMed
2.
go back to reference Nicholls JM, Agathanggelou A, Fung K, Zeng X, Niedobitek G: The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol 1997, 183: 164-168. 10.1002/(SICI)1096-9896(199710)183:2<164::AID-PATH919>3.3.CO;2-ACrossRefPubMed Nicholls JM, Agathanggelou A, Fung K, Zeng X, Niedobitek G: The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol 1997, 183: 164-168. 10.1002/(SICI)1096-9896(199710)183:2<164::AID-PATH919>3.3.CO;2-ACrossRefPubMed
3.
go back to reference Raab-Traub N: Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002, 12: 431-441. 10.1016/S1044579X0200086XCrossRefPubMed Raab-Traub N: Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002, 12: 431-441. 10.1016/S1044579X0200086XCrossRefPubMed
4.
go back to reference Niedobitek G, Fahraeus R, Herbst H, Latza U, Ferszt A, Klein G, Stein H: The Epstein-Barr virus encoded membrane protein (LMP) induces phenotypic changes in epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol 1992, 62: 55-59.CrossRefPubMed Niedobitek G, Fahraeus R, Herbst H, Latza U, Ferszt A, Klein G, Stein H: The Epstein-Barr virus encoded membrane protein (LMP) induces phenotypic changes in epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol 1992, 62: 55-59.CrossRefPubMed
5.
go back to reference Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T: Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 2001, 159: 27-33.PubMedCentralCrossRefPubMed Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T: Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 2001, 159: 27-33.PubMedCentralCrossRefPubMed
6.
go back to reference Jeon YK, Lee BY, Kim JE, Lee SS, Kim CW: Molecular characterization of Epstein-Barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea. Head Neck 2004, 26: 573-583. 10.1002/hed.10370CrossRefPubMed Jeon YK, Lee BY, Kim JE, Lee SS, Kim CW: Molecular characterization of Epstein-Barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea. Head Neck 2004, 26: 573-583. 10.1002/hed.10370CrossRefPubMed
7.
go back to reference Shao JY, Ernberg I, Biberfeld P, Heiden T, Zeng YX, Hu LF: Epstein-Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma. Anticancer Res 2004, 24: 2309-2318.PubMed Shao JY, Ernberg I, Biberfeld P, Heiden T, Zeng YX, Hu LF: Epstein-Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma. Anticancer Res 2004, 24: 2309-2318.PubMed
8.
go back to reference Heussinger N, Buttner M, Ott G, Brachtel E, Pilch BZ, Kremmer E, Niedobitek G: Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 2004, 203: 696-699. 10.1002/path.1569CrossRefPubMed Heussinger N, Buttner M, Ott G, Brachtel E, Pilch BZ, Kremmer E, Niedobitek G: Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 2004, 203: 696-699. 10.1002/path.1569CrossRefPubMed
9.
go back to reference Seto E, Yang L, Middeldorp J, Sheen TS, Chen JY, Fukayama M, Eizuru Y, Ooka T, Takada K: Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 2005, 76: 82-88. 10.1002/jmv.20327CrossRefPubMed Seto E, Yang L, Middeldorp J, Sheen TS, Chen JY, Fukayama M, Eizuru Y, Ooka T, Takada K: Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 2005, 76: 82-88. 10.1002/jmv.20327CrossRefPubMed
10.
go back to reference Meij P, Vervoort MB, Aarbiou J, van Dissel P, Brink A, Bloemena E, Meijer CJ, Middeldorp JM: Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J Infect Dis 1999, 179: 1108-1115. 10.1086/314704CrossRefPubMed Meij P, Vervoort MB, Aarbiou J, van Dissel P, Brink A, Bloemena E, Meijer CJ, Middeldorp JM: Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J Infect Dis 1999, 179: 1108-1115. 10.1086/314704CrossRefPubMed
11.
go back to reference Xu J, Ahmad A, D'Addario M, Knafo L, Jones JF, Prasad U, Dolcetti R, Vaccher E, Menezes J: Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J Immunol 2000, 164: 2815-2822.CrossRefPubMed Xu J, Ahmad A, D'Addario M, Knafo L, Jones JF, Prasad U, Dolcetti R, Vaccher E, Menezes J: Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J Immunol 2000, 164: 2815-2822.CrossRefPubMed
12.
go back to reference Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM: Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 2004, 190: 53-62. 10.1086/421245CrossRefPubMed Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM: Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 2004, 190: 53-62. 10.1086/421245CrossRefPubMed
13.
go back to reference Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM: Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 2005, 75: 593-602. 10.1002/jmv.20310CrossRefPubMed Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM: Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 2005, 75: 593-602. 10.1002/jmv.20310CrossRefPubMed
14.
go back to reference Zhang JX, Chen HL, Zong YS, Chan KH, Nicholls J, Middeldorp JM, Sham JS, Griffin BE, Ng MH: Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol 1998, 55: 227-233. 10.1002/(SICI)1096-9071(199807)55:3<227::AID-JMV8>3.0.CO;2-3CrossRefPubMed Zhang JX, Chen HL, Zong YS, Chan KH, Nicholls J, Middeldorp JM, Sham JS, Griffin BE, Ng MH: Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol 1998, 55: 227-233. 10.1002/(SICI)1096-9071(199807)55:3<227::AID-JMV8>3.0.CO;2-3CrossRefPubMed
15.
go back to reference Daoud J, Toumi N, Bouaziz M, Ghorbel A, Jlidi R, Drira MM, Frikha M: Nasopharyngeal carcinoma in childhood and adolescence: analysis of a series of 32 patients treated with combined chemotherapy and radiotherapy. Eur J Cancer 2003, 39: 2349-2354. 10.1016/S0959-8049(03)00512-4CrossRefPubMed Daoud J, Toumi N, Bouaziz M, Ghorbel A, Jlidi R, Drira MM, Frikha M: Nasopharyngeal carcinoma in childhood and adolescence: analysis of a series of 32 patients treated with combined chemotherapy and radiotherapy. Eur J Cancer 2003, 39: 2349-2354. 10.1016/S0959-8049(03)00512-4CrossRefPubMed
16.
go back to reference Khabir A, Ghorbel A, Daoud J, Frikha M, Drira MM, Laplanche A, Busson P, Jlidi R: Similar BCL-X but different BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detect Prev 2003, 27: 250-255. 10.1016/S0361-090X(03)00098-9CrossRefPubMed Khabir A, Ghorbel A, Daoud J, Frikha M, Drira MM, Laplanche A, Busson P, Jlidi R: Similar BCL-X but different BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detect Prev 2003, 27: 250-255. 10.1016/S0361-090X(03)00098-9CrossRefPubMed
17.
go back to reference Khabir A, Sellami A, Sakka M, Ghorbel AM, Daoud J, Frikha M, Drira MM, Busson P, Jlidi R: Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 2000, 6: 3932-3936.PubMed Khabir A, Sellami A, Sakka M, Ghorbel AM, Daoud J, Frikha M, Drira MM, Busson P, Jlidi R: Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 2000, 6: 3932-3936.PubMed
18.
go back to reference Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E, Ben-Izhak O: Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol 2003, 16: 1035-1040. 10.1097/01.MP.0000089778.48167.91CrossRefPubMed Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E, Ben-Izhak O: Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol 2003, 16: 1035-1040. 10.1097/01.MP.0000089778.48167.91CrossRefPubMed
19.
go back to reference Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, Havouis S, Ferradini L, Bosq J, Tursz T, Busson P: Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res 1999, 59: 924-930.PubMed Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, Havouis S, Ferradini L, Bosq J, Tursz T, Busson P: Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res 1999, 59: 924-930.PubMed
20.
go back to reference Prince S, Keating S, Fielding C, Brennan P, Floettmann E, Rowe M: Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J Virol 2003, 77: 5000-5007. 10.1128/JVI.77.8.5000-5007.2003PubMedCentralCrossRefPubMed Prince S, Keating S, Fielding C, Brennan P, Floettmann E, Rowe M: Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J Virol 2003, 77: 5000-5007. 10.1128/JVI.77.8.5000-5007.2003PubMedCentralCrossRefPubMed
21.
go back to reference Sbih-Lammali F, Djennaoui D, Belaoui H, Bouguermouh A, Decaussin G, Ooka T: Transcriptional expression of Epstein-Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinoma. J Med Virol 1996, 49: 7-14. PublisherFullText 10.1002/(SICI)1096-9071(199605)49:1<7::AID-JMV2>3.0.CO;2-ACrossRefPubMed Sbih-Lammali F, Djennaoui D, Belaoui H, Bouguermouh A, Decaussin G, Ooka T: Transcriptional expression of Epstein-Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinoma. J Med Virol 1996, 49: 7-14. PublisherFullTex​t 10.1002/(SICI)1096-9071(199605)49:1<7::AID-JMV2>3.0.CO;2-ACrossRefPubMed
22.
go back to reference Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB: Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988, 69 ( Pt 5): 1051-1065.CrossRef Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB: Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988, 69 ( Pt 5): 1051-1065.CrossRef
23.
go back to reference Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, et al.: Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988, 42: 329-338.CrossRefPubMed Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, et al.: Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988, 42: 329-338.CrossRefPubMed
24.
go back to reference Chen F, Hu LF, Ernberg I, Klein G, Winberg G: Coupled transcription of Epstein-Barr virus latent membrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas. J Gen Virol 1995, 76 ( Pt 1): 131-138.CrossRefPubMed Chen F, Hu LF, Ernberg I, Klein G, Winberg G: Coupled transcription of Epstein-Barr virus latent membrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas. J Gen Virol 1995, 76 ( Pt 1): 131-138.CrossRefPubMed
25.
go back to reference Brooks L, Yao QY, Rickinson AB, Young LS: Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992, 66: 2689-2697.PubMedCentralPubMed Brooks L, Yao QY, Rickinson AB, Young LS: Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992, 66: 2689-2697.PubMedCentralPubMed
26.
go back to reference Dietz A, Logothetis CA, Helbig M, Flechtenmacher C, Rudat V, Dollner R, Wallner F, Bosch FX: Prognostic Impact of EBV-Related LMP-1, Histologic Type, and Environmental Factors in Nasopharyngeal Carcinoma in a German Population. Onkologie 2004, 27: 345-350. 10.1159/000079086CrossRefPubMed Dietz A, Logothetis CA, Helbig M, Flechtenmacher C, Rudat V, Dollner R, Wallner F, Bosch FX: Prognostic Impact of EBV-Related LMP-1, Histologic Type, and Environmental Factors in Nasopharyngeal Carcinoma in a German Population. Onkologie 2004, 27: 345-350. 10.1159/000079086CrossRefPubMed
27.
go back to reference Jiwa NM, Oudejans JJ, Dukers DF, Vos W, Horstman A, van der Valk P, Middledorp JM, Walboomers JM, Meijer CJ: Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases. J Clin Pathol 1995, 48: 438-442.PubMedCentralCrossRefPubMed Jiwa NM, Oudejans JJ, Dukers DF, Vos W, Horstman A, van der Valk P, Middledorp JM, Walboomers JM, Meijer CJ: Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases. J Clin Pathol 1995, 48: 438-442.PubMedCentralCrossRefPubMed
28.
go back to reference Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS: The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A 2002, 99: 10084-10089. 10.1073/pnas.152059399PubMedCentralCrossRefPubMed Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS: The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A 2002, 99: 10084-10089. 10.1073/pnas.152059399PubMedCentralCrossRefPubMed
29.
go back to reference Takeshita H, Yoshizaki T, Miller WE, Sato H, Furukawa M, Pagano JS, Raab-Traub N: Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 1999, 73: 5548-5555.PubMedCentralPubMed Takeshita H, Yoshizaki T, Miller WE, Sato H, Furukawa M, Pagano JS, Raab-Traub N: Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 1999, 73: 5548-5555.PubMedCentralPubMed
30.
go back to reference Hu LF, Chen F, Zhen QF, Zhang YW, Luo Y, Zheng X, Winberg G, Ernberg I, Klein G: Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 1995, 31A: 658-660. 10.1016/0959-8049(94)00468-KCrossRefPubMed Hu LF, Chen F, Zhen QF, Zhang YW, Luo Y, Zheng X, Winberg G, Ernberg I, Klein G: Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 1995, 31A: 658-660. 10.1016/0959-8049(94)00468-KCrossRefPubMed
31.
go back to reference Mann KP, Staunton D, Thorley-Lawson DA: Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol 1985, 55: 710-720.PubMedCentralPubMed Mann KP, Staunton D, Thorley-Lawson DA: Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol 1985, 55: 710-720.PubMedCentralPubMed
32.
go back to reference Henle W, Henle G, Zajac BA, Pearson G, Waubke R, Scriba M: Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science 1970, 169: 188-190.CrossRefPubMed Henle W, Henle G, Zajac BA, Pearson G, Waubke R, Scriba M: Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science 1970, 169: 188-190.CrossRefPubMed
Metadata
Title
EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas
Authors
Abdelmajid Khabir
Hela Karray
Sandrine Rodriguez
Mathieu Rosé
Jamel Daoud
Mounir Frikha
Tahia Boudawara
Jaap Middeldorp
Rachid Jlidi
Pierre Busson
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2005
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-2-39

Other articles of this Issue 1/2005

Virology Journal 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine